Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
Discover More about Global Responsibility
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Discover More about Global Partnering
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Menarini Blog
Follow Us
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Our Job Portal
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
2020 - 01 - 27
Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
- Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® (ALOXI®) in Russia and CIS region from January 2020
- The two products will provide clinicians and patients with a comprehensive offering to manage chemotherapy-induced nausea and vomiting
Lugano, Switzerland and Berlin, Germany, January 27, 2020: Helsinn Group (“Helsinn”), a Swiss pharmaceutical group focused on building quality cancer care products, has granted exclusive licensing rights to commercialize AKYNZEO® and ONICIT® (ALOXI®) in Russia and the CIS region for the prevention of chemotherapy-induced nausea and vomiting (CINV) to Berlin-Chemie AG (“Berlin-Chemie”), the German-based affiliate of the Menarini Group.
AKYNZEO®, a fixed dose combination anti-emetic therapy targeting both critical pathways of acute and delayed CINV, was granted registration in Russia in October 2019 and the product will be launched in the country in 2020.
ONICIT®, an anti-emetic for the prevention of CINV, was registered in Russia in 2011 and will be relaunched with AKYNZEO®.
Besides Russia, the licensing agreements with Berlin-Chemie cover the following territories: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. AKYNZEO® has obtained a registration in Ukraine and Kazakhstan while ALOXI® holds a registration in Ukraine.
Under the terms of the agreements, Helsinn will retain all international development rights, including clinical development activities, and the supply of AKYNZEO® and ONICIT/®ALOXI®. Berlin-Chemie will have the exclusive rights to promote, distribute and commercialize AKYNZEO® and ONICIT®/ALOXI® in all countries of the assigned territories.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: “We’re delighted to have signed these agreements with Berlin-Chemie, which has established a strong presence and recognition in Russia and the CIS region. We look forward to being able to offer cancer patients greater choice for treating CINV, which remains a major issue during chemotherapy.”
“This is an important step for cancer patients across Russia and the CIS region. We look forward to working closely with Helsinn as we seek to launch AKYNZEO® and re-launch ONICIT® in the year ahead. We have been impressed by Helsinn’s commitment to the highest quality cancer care products and are pleased to extend our partnership with them.” said Michael Sirotovitch, COO of Berlin-Chemie AG.